Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Bronte Capital Amalthea Fund 2023 Q2 Investor Letter | Buyside Digest

Back to Fund Profile (Bronte Capital Amalthea Fund)

Primary Source Intelligence • Q2 2023 Letter Analysis

Bronte Capital Amalthea Fund Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Bronte Capital Amalthea Fund. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

Annualized+9.67%

Positioning StanceConstructive

GeographyGlobal

Digest Analysis

Quick Take

"Amalthea Fund's long/short strategy faced headwinds in June despite strong short book performance. Holdings in animal genetics and biotechnology suffered cyclical pressures, while managers warn of dangerous speculative excess returning to markets."

Executive Summary

Bronte Capital's Amalthea Fund declined 1.35% in June while global markets surged, bringing full-year returns to 14.75%. The fund's short book performed well despite hostile conditions, gaining alpha through extensive diversification across 500 names. However, the long book struggled with less than 0.5% gains, hurt by exposure to engineered goods companies facing cyclical headwinds. Key holdings include Genus, a pig genetics leader suffering from Chinese pork market downturn, and Regeneron, which faced FDA rejection of high-dose EYLEA due to manufacturing issues at contractor Catalent. The managers express concern about returning speculative excess reminiscent of 2021, with irrational exuberance driving garbage AI stocks higher. Despite near-term challenges, they remain confident in their thesis around superior businesses in animal genetics and biotechnology, believing Chinese demand will recover and Regeneron's pipeline will drive future growth. The fund maintains cautious positioning with lighter leverage given market conditions.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

68%

CautiousHigh

Moderate (68%)

The fund demonstrates moderate-high conviction through concentrated positions in named holdings like Genus and Regeneron, with detailed thesis explanations and willingness to hold through volatility. However, hedged language around market conditions and some uncertainty about position sizing caps the score below 0.75.

Growth Outlook

30%

BearishBullish

Bearish (30%)

The managers express significant concern about market conditions, describing irrational exuberance, speculative urges, and comparing current environment to the 2021 bubble. They acknowledge being wrong about their cautious 2023 positioning but maintain fearful outlook.

Risk Appetite

40%

DefensiveAggressive

Defensive (40%)

The fund ran leverage at the lighter end of their historic range, indicating defensive positioning. They maintain extensive short book diversification and express caution about adding to positions despite opportunities.

Capital Deployment

43%

De-riskingDeploying

Net Neutral (43%)

The fund explicitly ran leverage at the lighter end of their historic range, indicating reduced deployment. While they discuss potential additions to Regeneron, they cite constraints and maintain cautious approach to new capital deployment.

Forward Guidance

35%

CautiousExpansionary

Cautious (35%)

While they see substantial opportunity in their current book, the managers emphasize patience and risk management rather than aggressive deployment. They expect the current speculative period to end but are not rushing to capitalize.

Language Signal

33%

BearishBullish

Bearish (33%)

Language is dominated by risk-focused terms including irrational exuberance, fearful, nightmare scenarios, and bubble comparisons. Positive language around specific holdings is offset by broader market warnings.

Perceived Risk

75%

Low RiskElevated

Elevated Risk (75%)

High perceived risk is evident through extensive discussion of irrational exuberance, bubble comparisons to 2021, manufacturing risks at Catalent, and warnings about speculative excess. Multiple specific risk scenarios are detailed throughout the letter.

Opportunity Density

60%

ScarceAbundant

Selective (60%)

The managers see substantial opportunity in their current book and identify specific catalysts for holdings, but emphasize selectivity and patience. They acknowledge missing opportunities like NVIDIA while maintaining focus on their specialized areas.

Time Horizon

75%

Short-TermLong-Term

Decade+ (75%)

The fund demonstrates multi-year investment horizon through willingness to hold Genus through cyclical downturn and confidence in long-term Chinese demand recovery. They describe Regeneron pipeline as promising over time and emphasize patient capital approach despite near-term volatility.